The potential, open-label, randomized, multicenter trial was made to assess the protection and efficacy of BAX 817 in male individuals ages 12 to 65 with hemophilia A or B with inhibitors over a 6-month period using on-demand therapy. The trial fulfilled its main endpoint of successful quality of severe bleeding episodes at 12 hours with both on-demand treatment regimens, dosing either 3×90 µg/kg or 1×270 µg/kg, with a standard success rate of 92 % . Further, 89 % of sufferers in the trial accomplished sustained bleeding control for all severe bleeding episodes 24hours after infusion. ''The advancement of inhibitors remains probably the most significant challenges in treating hemophilia, as it can place patients at increased risk for life-threatening complications caused by difficult-to-treat bleeding episodes,'' stated John Orloff, M.D., vice president and global mind of development and analysis at Baxter BioScience.Pet research and it’s benefits to both humans and animals From preventing polio to finding cures for cancer patients, animal analysis has saved countless lives. Using animals in research is a concern to some; nevertheless, the benefits produced from the ethical, humane usage of laboratory animals for biomedical research are huge. Nearly every major medical breakthrough within the last 100 years has been attained by research with pets. ‘These animals are heroes. Their contribution to discovering life-saving developments in medication and science-for both humans-is and pets tremendous,’ said Jon Klingborg, DVM, president of the California Veterinary Medical Association .

Other entries from category "nephrology":

Random entries